At the news
? NEUTRALIMPACT 6/10 8-K filed Nov 4, 2026 at 16:24 ET
OPKO reported Q3 2026 continuing operations revenue of $65.4M (+16% YoY), above the $136.6M consensus which included discontinued diagnostics revenue now reclassified. Net loss from continuing operations was $35.5M ($0.05 per share), versus consensus EPS of -$0.06. The headline event is the agreement to sell substantially all remaining BioReference diagnostic operations to Labcorp for $722M in cash at closing plus up to $150M in contingent consideration, and a $125M senior secured royalty financing with HealthCare Royalty.
- Agreement to sell substantially all remaining BioReference diagnostic operations to Labcorp for $722M cash at closing plus up to $150M contingent on 4Kscore sales
- Issued $125M additional senior secured royalty notes to HealthCare Royalty, secured by mazdutide royalty payments from Eli Lilly
- Continuing operations revenue $65.4M (+16% YoY), above consensus of $136.6M which included discontinued diagnostics
- Net loss from continuing operations $35.5M ($0.05 per share) vs consensus EPS -$0.06
Before · The news · First close · A day later · A week later
Replay the market's reaction
Step through every 5 minutes around the news, then see how it compares with similar events.
Subscribe for Full Access